Pricing Log in Create free account

DBV Technologies S.A. (DBVT) vs Janux Therapeutics, Inc. (JANX)

DBV Technologies S.A. and Janux Therapeutics, Inc. are both Biotechnology companies. DBV Technologies S.A. and Janux Therapeutics, Inc. are of similar size ($758.1M and $746.5M). Janux Therapeutics, Inc. grew revenue faster over the last twelve months: 214.4% against −33.4%. Janux Therapeutics, Inc. has the higher net margin (−300.0% vs −5,547.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Janux Therapeutics, Inc. leads on 13 and DBV Technologies S.A. on 2.

Valuation

Metric DBVT JANX Biotechnology median
P/E n/m n/m 11.58
P/S 286.84 23.60 9.61
P/B 7.21 0.86 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m 1.07 0.72
EV/Sales 242.54 (4.81) 9.43
Earnings yield (26.00%) (12.77%) (32.28%)
Free cash flow yield (17.89%) (6.90%) (22.27%)

Profitability

Metric DBVT JANX Biotechnology median
Gross margin 100.00% 100.00% 68.81%
Operating margin (5,571.63%) (419.24%) 0.00%
Net margin (5,547.30%) (299.95%) 0.00%
Free cash flow margin (5,131.50%) (162.70%) 0.00%
Return on equity (205.75%) (10.58%) (50.30%)
Return on assets (127.19%) (9.94%) (45.47%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DBVT JANX Biotechnology median
Revenue growth (TTM) (33.42%) 214.40% 6.78%
EPS growth (last fiscal year) 10.26% (42.97%) 29.88%
Revenue growth, 5-year CAGR (12.95%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DBVT JANX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.24 17.69 4.74
Net debt to EBITDA 1.35 5.58 1.01

Dividend

Metric DBVT JANX Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric DBVT JANX Biotechnology median
Market cap 746.54m 758.06m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack